Alzheimer's Disease Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2030

1.1 Alzheimer's market forecast to see double-digit sales growth out to 2030
1.2 Eisai, Biogen, and Lilly are forecast to lead the AD market in 2030
1.3 Opportunities to fulfil key unmet needs will remain
1.4 Novel late-stage pipeline drugs will be a key driver of growth
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Disease staging systems
3.3 Symptoms
3.4 Prognosis
3.5 Quality of life

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.5 Epidemiological Forecast for AD (2020-30)
4.5.1 Total prevalent cases of AD
4.5.2 Age-specific total prevalent cases of AD
4.5.3 Sex-specific total prevalent cases of AD
4.5.4 Total prevalent cases of AD by severity
4.5.5 Diagnosed prevalent cases of AD
4.5.6 Age-specific diagnosed prevalent cases of AD
4.5.7 Sex-specific diagnosed prevalent cases of AD
4.5.8 Diagnosed prevalent cases of AD by severity
4.5.9 Total prevalent cases of MCI
4.5.10 Age-specific total prevalent cases of MCI
4.5.11 Sex-specific total prevalent cases of MCI
4.5.12 Diagnosed prevalent cases of MCI
4.5.13 Age-specific diagnosed prevalent cases of MCI
4.5.14 Sex-specific diagnosed prevalent cases of MCI
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6.1 Overview

7.1 Overview
7.2 Wider availability of DMTs
7.3 Diagnosis in the prodromal or presymptomatic stages
7.4 Improved control of symptoms
7.5 Easier access to treatment

8.1 Overview
8.1.1 Targeting Aß
8.1.2 Novel MOAs
8.1.3 Combination therapies
8.2 Clinical trials design
8.2.1 Endpoints
8.2.2 Inclusion/exclusion criteria

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment
10.2.1 Injectable DMTs
10.2.2 Oral DMTs
10.2.3 Therapies for agitation associated with AD
10.2.3 Other symptomatic therapies

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
12.5 China
12.5.1 Forecast
12.5.2 Key events
12.5.3 Drivers and barriers

13.1 Bibliography
13.2 Abbreviations
13.3 AD clinical development pipeline
13.4 Methodology
13.4.1 Forecasting methodology
13.5 Primary research - KOLs and payers interviewed for this report
13.5.1 KOLs
13.5.2 Payers
13.6 Primary research - prescriber survey
13.7 About the authors
13.7.1 Analyst
13.7.2 Therapy Area Director
13.7.3 Epidemiologist
13.7.4 Managing Epidemiologist
13.7.5 Vice President of Disease Analysis and Intelligence
13.7.6 Global Head and EVP of Healthcare Operations and Strategy

Table 1: MCI and AD: Key metrics in the 8MM
Table 2: Three-stage classification of AD
Table 3: The seven-stage Reisburg Scale of AD
Table 4: Proposed NIA-AA staging classification for preclinical AD
Table 5: Common symptoms of AD
Table 6: Risk factors and comorbidities for AD
Table 7: Summary of NINCDS-ARDA diagnostic criteria for AD
Table 8: Most prescribed drugs for AD by class in the 8MM
Table 9: Most prescribed off-label drug classes for secondary AD symptoms by class in the 8MM
Table 10: Treatment Guidelines for AD
Table 11: AD market - global drivers and barriers, 2020-30
Table 12: Key events impacting sales for AD in the US, 2020-30
Table 13: AD market - drivers and barriers in the US, 2020-30
Table 14: Key events impacting sales for AD in the 5EU, 2020-30
Table 15: AD market - drivers and barriers in the 5EU, 2020-30
Table 16: Key events impacting sales for AD in Japan, 2020-30
Table 17: AD market - drivers and barriers in Japan, 2020-30
Table 18: Key events impacting sales for AD in China, 2020-30
Table 19: AD market - drivers and barriers in China, 2020-30
Table 20: AD clinical development pipeline by drug class
Table 21: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for AD in 2020 and 2030
Figure 2: Analysis of the company portfolio gap in AD during the forecast period
Figure 3: Competitive assessment of the injectable DMTs benchmarked against Aduhelm
Figure 4: AD biomarker tests by [athophysiology
Figure 5: 8MM, total prevalence of AD (%), men and women, ages =60 years, 2020
Figure 6: 8MM, total prevalence of MCI (%), men and women, ages =60 years, 2020
Figure 7: 8MM, sources used and not used to forecast the total prevalent cases of AD based on the DSM-IV and clinical criteria
Figure 8: 8MM, sources used and not used to forecast the total prevalent cases of MCI
Figure 9: 8MM, sources used to forecast the total prevalent cases of AD by severity
Figure 10: 8MM, total prevalent cases of AD, both sexes, ages =60 years, 2020
Figure 11: 8MM total prevalent cases of AD, by sex, ages =60 years, N, 2020
Figure 12: 8MM, total prevalent cases of AD, by age, both sexes, N, 2020
Figure 13: 8MM, total prevalent cases of AD, by severity, both sexes, ages =60 years, N, 2020
Figure 14: 8MM, diagnosed prevalent cases of AD, both sexes, ages =60 years, N, 2020
Figure 15: 8MM, diagnosed prevalent cases of AD, by sex, ages =60 years, N, 2020
Figure 16: 8MM, diagnosed prevalent cases of AD by age, both sexes, N, 2020
Figure 17: 8MM, diagnosed prevalent cases of AD by severity, both sexes, ages =60 years, N, 2020
Figure 18: 8MM, total prevalent cases of MCI, both sexes, ages =60 years
Figure 19: 8MM, total prevalent cases of MCI, by sex, ages =60 years, N, 2020
Figure 20: 8MM, total prevalent cases of MCI, by age, both sexes, N, 2020
Figure 21: 8MM, diagnosed prevalent cases of MCI, both sexes, ages =60 years
Figure 22: 8MM, diagnosed prevalent cases in MCI, by sex, ages =60 years, N, 2020
Figure 23: 8MM, diagnosed prevalent cases in MCI, by age, both sexes, N, 2020
Figure 24: 8MM, treatment algorithm for AD
Figure 25: 8MM, disease management timeline for AD
Figure 26: Unmet needs and opportunities in AD
Figure 27: Key late-stage trials for the promising pipeline agents that the analyst expects be licensed for AD in the 8MM during the forecast period
Figure 28: Key late-stage trials for the promising pipeline agents that the analyst expects be licensed for agitation associated with AD in the 8MM during the forecast period
Figure 29: Competitive assessment of the injectable pipeline DMTs benchmarked against Aduhelm (aducanumab)
Figure 30: Competitive assessment of the oral pipeline DMTs benchmarked against oral generic donepezil
Figure 31: Competitive assessment of the pipeline agents for agitation associated with AD benchmarked against Risperdal (risperidone)
Figure 32: Competitive assessment of the other symptomatic therapies benchmarked against donepezil (oral)
Figure 33: Analysis of the company portfolio gap in AD during the forecast period
Figure 34: Global (8MM) sales forecast by country for AD in 2020 and 2030
Figure 35: Global (8MM) sales forecast by class for AD in 2020 and 2030
Figure 36: Sales forecast by class for AD in the US in 2020 and 2030
Figure 37: Sales forecast by class for AD in the 5EU in 2020 and 2030
Figure 38: Sales forecast by class for AD in Japan in 2020 and 2030
Figure 39: Sales forecast by class for AD in China in 2020 and 2030